Image

Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence

Recruiting
18 years of age
Both
Phase N/A

Powered by AI

Overview

This is a prospective, open-label therapeutic interventional investigation designed to interrogate the efficacy and safety of individualized matched therapies in patients with pancreatic cancer at high risk of disease recurrence post-surgery.

Description

This is a prospective, open-label, therapeutic interventional investigation designed to interrogate the efficacy and safety of personalized matched therapy in pancreatic cancer patients who have completed all intended multimodal therapy, including resection of the pancreatic cancer tumor. Potential participants must have their tumor tissue or blood molecularly profiled with the results discussed by the Molecular Tumor Board, whether convened in person, virtually (e.g., WebEx), or in an electronic forum (e.g., email). Only those patients who agree to receive the Molecular Tumor Board-recommended matched therapy (i.e., study treatment) will be eligible and enrolled on the study.

Eligibility

Inclusion Criteria:

  1. Age ≥18 years.
  2. Pathologically confirmed pancreatic cancer (excluding neuroendocrine histology).
  3. Pancreatic tumor is surgically removed and
    1. patient has received multimodal therapy (neoadjuvant, sandwich or adjuvant chemotherapy ± radiation) or
    2. patient is ineligible for or refuses multimodal therapy.
  4. Patient has one of the following:
    1. Post-surgical cancer antigen (CA) 19-9 elevation (> 35 U/mL at least 6 weeks post-surgical resection) in the setting of bilirubin < 2 mg/dL (unless bilirubin elevation is consistent with Gilbert's syndrome) OR
    2. High-risk pathological features, defined as positive surgical margin or lymph node involvement in cancer.
  5. Patient has no definitive measurable disease recurrence or metastatic disease at the

    time of first post-surgical imaging (in those with high-risk pathological features) or within four weeks of elevated CA 19-9 value as evidenced by appropriate imaging.

  6. Laboratory values:
    1. Absolute neutrophil count (ANC) ≥ 1.0 × 109/L.
    2. Platelet count ≥ 75,000/mm^3 (125 × 109/L).
    3. Hemoglobin (Hgb) ≥ 8 g/dL.
    4. aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT), alanine transaminase (ALT) serum glutamate-pyruvate transaminase (SGPT) ≤ 5 × upper limit of normal range (ULN).
  7. Eastern Cooperative Oncology Group (ECOG) Performance Status < 3.
  8. At the time of treatment, patient should be off other anti-tumor agents for at least five half-lives of the agent or three weeks from the last day of treatment, whichever is shorter.
  9. Able to swallow and retain oral medication, if needed.
  10. Pregnancy It is not known what effects matched therapy has on human pregnancy or development of the embryo or fetus. Therefore, female subjects participating in this study should avoid becoming pregnant, and male subjects should avoid impregnating a female partner. Nonsterilized female subjects of reproductive age and male subjects should use effective methods of contraception through defined periods during and after study treatment as specified below.

    Female participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    • Not a female of childbearing potential (FCBP), defined as all female patients that were not in post-menopause for at least one year or are surgically sterile, OR
    • An FCBP must have a negative serum pregnancy test and agree to use at least one form of pregnancy prevention during the study for at least one month after treatment discontinuation unless otherwise noted by the agent(s) USPI, which the FCBP must follow.
             Male participants: A male participant, even if surgically sterilized (i.e., status
             post vasectomy), must use a form of barrier pregnancy prevention approved by the
             investigator or treating physician during the study and for at least one month after
             treatment discontinuation and refrain from donating sperm during this period unless
             otherwise noted by the agent(s) USPI, which the male participant must follow.
         11. Patient must be presented at the Molecular Tumor Board (MTB) and agree to receive the
             MTB-recommended therapy.
         12. Ability to understand a written informed consent document, and the willingness to sign
             it.
               1. Patients presented at the MTB prior to signing consent are eligible to be on
                  study. Patients do not need to be presented again at the MTB prior to starting
                  therapy on trial unless six months elapse between consent and start of study
                  treatment.
        Exclusion Criteria:
        A potential study subject who meets any of the following exclusion criteria is ineligible
        to participate in the study.
          1. CA 19-9 non-producers, unless high-risk pathological features present.
          2. Receiving concomitant investigational agent(s) for pancreatic ductal adenocarcinoma
             (PDAC).
          3. Radiographic evidence of metastatic disease.
          4. Inability to ingest study drugs by mouth.
          5. Diarrheal bowel movements > 6 per day postoperatively on maximal medical therapy.
          6. Patient has active, untreated, or uncontrolled bacterial, viral, or fungal
             infection(s) requiring systemic intravenous therapy.
          7. Patient has undergone or planned major surgery other than diagnostic surgery (i.e.,
             surgery done to obtain a biopsy for diagnosis without removal of an organ) within four
             weeks prior to Day 1 of study therapy.
          8. Patient has a history of allergy or hypersensitivity to the study drug(s) or any of
             the excipients.
          9. Uncontrolled concurrent illness, including, but not limited to, unstable angina
             pectoris, uncontrolled and clinically significant cardiac arrhythmia, or psychiatric
             illness/social situations that would limit compliance with study requirements.
         10. Is pregnant or breastfeeding or any patient with childbearing potential not using
             adequate pregnancy prevention.

Study details

Pancreas Cancer

NCT06228599

Medical College of Wisconsin

1 May 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.